The outcomes of this randomized, multicenter, double-blinded phase III trial robustly establish the therapeutic equivalence between QL1209 and reference pertuzumab as neoadjuvant treatments for patients with HER2-positive, ER/PR-negative early-stage or locally advanced breast cancer. The gene discussed is ERBB2; the disease is breast cancer.